What the work claims
The method produces monoclonal antibodies of predefined, uniform specificity via immortal hybridomas derived from B-cell–myeloma fusions.
How it was done
Köhler and Milstein fused antibody-producing lymphocytes from immunized animals with immortal myeloma cells to create hybridomas. They reported continuous cultures of these fused cells secreting antibody of predefined specificity in Nature in 1975.
What holds up
The hybridoma technique reliably produced immortalised cell lines secreting monoclonal antibodies specific to known antigens. It enabled reproducible generation of antibodies with uniform specificity — unlike heterogeneous conventional antisera.
What does not
The work did not produce therapeutic antibodies. It did not demonstrate in vivo efficacy, clinical use, or human application. It did not quantify affinity, yield, stability, or batch-to-batch variation.
Why it matters beyond the lab
Monoclonal antibodies became essential for immuno-based diagnostic tests. They enabled precise identification, purification, and measurement of particular molecules — foundational for modern biomedicine and industrial assay development.
Is it worth your time
Yes. It established the first reproducible method to generate antibodies of uniform specificity — a tool that reshaped diagnostics, purification, and measurement in molecular biology.
